查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951933

多形性膠質母細胞瘤 (GBM) 治療市場分析及預測（至 2035 年）：按類型、產品類型、技術、應用、最終用戶、設備、疾病階段、服務、部署類型和功能分類

Glioblastoma Multiforme (GBM) Treatment Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Device, Stage, Services, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 366 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

多形性膠質母細胞瘤 (GBM) 治療市場預計將從 2024 年的 36 億美元成長到 2034 年的 81 億美元，複合年成長率約為 10%。 GBM 治療市場涵蓋針對侵襲性腦腫瘤的治療方法，包括手術、放射線治療、化療以及新興的免疫療法，旨在延長患者的生存期並提高其生活品質。分子診斷和個人化醫療的進步正在推動創新，而未被滿足的醫療需求和高發病率則推動了市場成長。策略合作和研發投資對於開發新型治療方法和改善治療效果至關重要。

由於治療方法的進步和研究投入的增加，膠質母細胞瘤（GBM）治療市場持續發展。化療是表現最佳的領域，其中Temozolomide因其能有效延長患者存活期而成為應用最廣泛的藥物。免疫療法是表現第二好的領域，由於查核點抑制劑和疫苗療法的良好前景，該領域發展勢頭強勁。這些創新正在重塑治療模式，並為改善患者預後帶來希望。放射線治療仍然是GBM治療的關鍵組成部分，立體定位放射放射線手術和調強放射線治療（IMRT）提高了治療精度，並最大限度地減少了對正常組織的損傷。外科治療領域也取得了進展，微創手術技術和神經導航系統提高了切除的準確性。基因療法和標靶藥物遞送系統等新興治療方法正引起廣泛關注，反映了精準醫療的趨勢。製藥公司和研究機構之間的合作正在加速新型療法的開發，為市場成長提供了廣泛的機會。

市場區隔
類型 化療、放射線治療、標靶治療、免疫療法、腫瘤治療領域
產品 藥品、醫療設備及治療方案
科技 基因療法、奈米技術、生物技術
適應症 原發性母細胞瘤、續發性母細胞瘤、復發性膠質母細胞瘤
最終用戶 醫院、專科診所、門診手術中心及研究機構
裝置 核磁共振掃描儀、CT掃描儀、PET掃描儀
階段 早期、晚期、復發期
服務 諮詢、診斷和治療服務
實施表格 本機部署、雲端部署、混合式部署
功能 診斷、治療和監測功能

多形性膠質母細胞瘤 (GBM) 治療市場充滿活力，主要參與者之間的市佔率分佈差異顯著。定價策略競爭激烈，反映了創新和新治療方法的推出。近期推出的產品主要集中在標靶治療和個人化醫療，旨在改善患者預後。市場正轉向包括免疫療法和基因編輯在內的新型治療方法，這些方法正在重塑治療模式，並為市場成長提供廣闊前景。競爭基準研究顯示，既有老牌製藥巨頭，也有新興生技公司，它們都佔據強大的市場地位。監管的影響，尤其是在北美和歐洲，對市場動態的塑造至關重要，嚴格的核准流程影響新產品上市的速度。競爭格局的特點是策略聯盟和併購，這些措施增強了企業的研發能力和市場覆蓋範圍。法律規範不斷完善，重點關注病人安全和療效，這在推動創新的同時，也帶來了合規性和市場准入的挑戰。

主要趨勢和促進因素：

多形性膠質母細胞瘤 (GBM) 治療市場正經歷著蓬勃發展，這主要得益於發病率的上升和治療方法的進步。關鍵趨勢包括個人化醫療的發展，它能夠根據個別基因譜進行治療，從而提高療效並改善患者預後。免疫療法已成為一種極具前景的治療選擇，它利用人體自身的免疫系統更有效地攻擊癌細胞。另一個關鍵促進因素是研發活動的活性化，催生了創新的藥物製劑和給藥機制。製藥公司與研究機構之間合作的加強正在加速新治療方法的發現。此外，孤兒藥的監管支持正在獎勵GBM治療方法的研發，進一步刺激市場擴張。新興市場擁有完善的醫療基礎設施，並且能夠更便利地獲得先進療法，這些市場蘊藏著許多機會。專注於提供價格合理且易於獲取的解決方案的公司將佔據有利地位，從而搶佔這個不斷成長的市場。此外，人工智慧 (AI) 在藥物研發和病患監測中的應用將透過提高治療的精準性和效率，徹底改變 GBM 的治療方式。隨著人們對癌症研究的興趣和投入不斷成長，GBM 治療市場有望持續進步和創新。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 化療
    • 放射治療
    • 標靶治療
    • 免疫療法
    • 腫瘤治療領域
  • 市場規模及預測：依產品分類
    • 藥物
    • 裝置
    • 治療方案
  • 市場規模及預測：依技術分類
    • 基因治療
    • 奈米科技
    • 生物技術
  • 市場規模及預測：依應用領域分類
    • 原發性母細胞瘤
    • 次發性細胞瘤
    • 復發性膠質母細胞瘤
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 門診手術中心
    • 研究所
  • 市場規模及預測：依設備分類
    • 核磁共振掃描儀
    • CT掃描儀
    • PET掃描儀
  • 市場規模及預測：依疾病階段分類
    • 早期
    • 高級階段
    • 復發期
  • 市場規模及預測：依服務分類
    • 諮詢服務
    • 診斷服務
    • 治療服務
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
    • 混合
  • 市場規模及預測：依功能分類
    • 診斷特徵
    • 按治療功能
    • 監控功能

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Kazia Therapeutics
  • Northwest Biotherapeutics
  • Del Mar Pharmaceuticals
  • Cortexyme
  • Vascular Biogenics
  • Agenus
  • Merrimack Pharmaceuticals
  • Diffusion Pharmaceuticals
  • Ziopharm Oncology
  • Oncoceutics
  • DNAtrix
  • Immunomic Therapeutics
  • Kintara Therapeutics
  • Medicenna Therapeutics
  • Candel Therapeutics
  • Immuno Cellular Therapeutics
  • Plus Therapeutics
  • Tocagen
  • Orbus Therapeutics
  • Bexion Pharmaceuticals

第9章：關於我們

簡介目錄
Product Code: GIS26463

Glioblastoma Multiforme (GBM) Treatment Market is anticipated to expand from $3.6 billion in 2024 to $8.1 billion by 2034, growing at a CAGR of approximately 10%. The Glioblastoma Multiforme (GBM) Treatment Market encompasses therapies targeting aggressive brain tumors, including surgery, radiation, chemotherapy, and emerging immunotherapies. It aims to extend patient survival and improve quality of life. Advances in molecular diagnostics and personalized medicine are driving innovation, while the high unmet need and prevalence spur market growth. Strategic collaborations and research investments are pivotal in developing novel treatments and enhancing therapeutic efficacy.

The Glioblastoma Multiforme (GBM) Treatment Market is evolving, driven by advancements in therapeutic approaches and increasing research investments. The chemotherapy segment leads in performance, with temozolomide being the most widely used due to its efficacy in extending patient survival. Immunotherapy is the second highest performing segment, gaining momentum with promising results from checkpoint inhibitors and vaccine-based therapies. These innovations are reshaping treatment paradigms, offering hope for improved patient outcomes. Radiation therapy remains a critical component of GBM treatment, with stereotactic radiosurgery and intensity-modulated radiation therapy enhancing precision and minimizing damage to healthy tissue. The surgical segment is also witnessing advancements, with minimally invasive techniques and neuro-navigation systems improving resection accuracy. Emerging treatment modalities, such as gene therapy and targeted drug delivery systems, are attracting significant interest, reflecting a shift towards personalized medicine. Collaborations between pharmaceutical companies and research institutions are accelerating the development of novel therapeutics, presenting lucrative opportunities for market growth.

Market Segmentation
TypeChemotherapy, Radiotherapy, Targeted Therapy, Immunotherapy, Tumor Treating Fields
ProductDrugs, Devices, Therapeutic Solutions
TechnologyGene Therapy, Nanotechnology, Biotechnology
ApplicationPrimary Glioblastoma, Secondary Glioblastoma, Recurrent Glioblastoma
End UserHospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
DeviceMRI Scanners, CT Scanners, PET Scanners
StageEarly Stage, Advanced Stage, Recurrent Stage
ServicesConsultation Services, Diagnostic Services, Treatment Services
DeploymentOn-premise, Cloud-based, Hybrid
FunctionalityDiagnostic Functionality, Therapeutic Functionality, Monitoring Functionality

The Glioblastoma Multiforme (GBM) Treatment Market is characterized by a dynamic landscape with diverse market share distribution among key players. Pricing strategies are increasingly competitive, reflecting both innovation and the introduction of new treatment modalities. Recent product launches have focused on targeted therapies and personalized medicine, aiming to improve patient outcomes. The market is witnessing a shift towards novel therapeutic approaches, including immunotherapy and gene editing, which are reshaping treatment paradigms and offering promising avenues for growth. Competition benchmarking reveals a robust presence of established pharmaceutical giants alongside emerging biotech firms. Regulatory influences, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent approval processes impacting the speed of new product introductions. The competitive landscape is marked by strategic collaborations and mergers, enhancing research capabilities and market reach. Regulatory frameworks continue to evolve, with an emphasis on patient safety and efficacy, driving innovation while presenting challenges in compliance and market entry.

Geographical Overview:

The Glioblastoma Multiforme (GBM) treatment market is witnessing varied growth patterns across different regions. North America remains at the forefront, driven by advanced healthcare infrastructure and significant research investments. The presence of leading pharmaceutical companies and active clinical trials contributes to its dominance. Europe follows, benefiting from strong regulatory support and increasing healthcare expenditure. The region's focus on innovative therapies and personalized medicine further propels market growth. Asia Pacific is emerging as a lucrative market, with rising healthcare awareness and improving medical facilities. Countries like China and India are investing heavily in healthcare, fostering growth in GBM treatment. Latin America and the Middle East & Africa are nascent markets with promising potential. Brazil and South Africa are key countries showing increased interest in modern oncology treatments. Enhanced healthcare policies and growing patient awareness in these regions are expected to drive demand for advanced GBM therapies, creating new growth pockets in the global market.

The Glioblastoma Multiforme (GBM) Treatment Market is significantly influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, reliance on imported pharmaceuticals prompts strategic shifts towards local R&D investments to mitigate tariff impacts. China's focus on self-sufficiency in drug production is accelerated by trade restrictions, fostering innovation in GBM therapies. Taiwan's robust biotech sector remains vital, yet faces geopolitical risks from regional tensions. Globally, the GBM treatment market is experiencing steady growth, driven by advancements in personalized medicine and immunotherapy. By 2035, market evolution will hinge on collaborative research and diversified supply chains. Middle East conflicts could exacerbate supply chain disruptions, indirectly affecting production costs and timelines through volatile energy prices.

Key Trends and Drivers:

The Glioblastoma Multiforme (GBM) Treatment Market is experiencing dynamic growth, propelled by increasing incidence rates and advancements in therapeutic approaches. A key trend is the development of personalized medicine, which tailors treatment based on individual genetic profiles, enhancing efficacy and patient outcomes. Immunotherapy is gaining traction as a promising treatment option, leveraging the body's immune system to combat cancer cells more effectively. Another significant driver is the rise in research and development activities, leading to innovative drug formulations and delivery mechanisms. The growing collaboration between pharmaceutical companies and research institutions is accelerating the pace of new treatment discoveries. Additionally, regulatory support for orphan drugs provides incentives for developing GBM therapies, fostering further market expansion. Opportunities abound in emerging markets where healthcare infrastructure is improving, and access to advanced treatments is expanding. Companies focusing on affordable and accessible solutions are well-positioned to capture these growing markets. The integration of artificial intelligence in drug discovery and patient monitoring is also set to revolutionize the landscape, offering precision and efficiency in GBM treatment. As awareness and investment in cancer research grow, the GBM Treatment Market is poised for sustained advancement and innovation.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Services
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Chemotherapy
    • 4.1.2 Radiotherapy
    • 4.1.3 Targeted Therapy
    • 4.1.4 Immunotherapy
    • 4.1.5 Tumor Treating Fields
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Drugs
    • 4.2.2 Devices
    • 4.2.3 Therapeutic Solutions
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Gene Therapy
    • 4.3.2 Nanotechnology
    • 4.3.3 Biotechnology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Primary Glioblastoma
    • 4.4.2 Secondary Glioblastoma
    • 4.4.3 Recurrent Glioblastoma
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Specialty Clinics
    • 4.5.3 Ambulatory Surgical Centers
    • 4.5.4 Research Institutes
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 MRI Scanners
    • 4.6.2 CT Scanners
    • 4.6.3 PET Scanners
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Early Stage
    • 4.7.2 Advanced Stage
    • 4.7.3 Recurrent Stage
  • 4.8 Market Size & Forecast by Services (2020-2035)
    • 4.8.1 Consultation Services
    • 4.8.2 Diagnostic Services
    • 4.8.3 Treatment Services
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-premise
    • 4.9.2 Cloud-based
    • 4.9.3 Hybrid
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Diagnostic Functionality
    • 4.10.2 Therapeutic Functionality
    • 4.10.3 Monitoring Functionality

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Device
      • 5.2.1.7 Stage
      • 5.2.1.8 Services
      • 5.2.1.9 Deployment
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Device
      • 5.2.2.7 Stage
      • 5.2.2.8 Services
      • 5.2.2.9 Deployment
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Device
      • 5.2.3.7 Stage
      • 5.2.3.8 Services
      • 5.2.3.9 Deployment
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Device
      • 5.3.1.7 Stage
      • 5.3.1.8 Services
      • 5.3.1.9 Deployment
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Device
      • 5.3.2.7 Stage
      • 5.3.2.8 Services
      • 5.3.2.9 Deployment
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Device
      • 5.3.3.7 Stage
      • 5.3.3.8 Services
      • 5.3.3.9 Deployment
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Device
      • 5.4.1.7 Stage
      • 5.4.1.8 Services
      • 5.4.1.9 Deployment
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Device
      • 5.4.2.7 Stage
      • 5.4.2.8 Services
      • 5.4.2.9 Deployment
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Device
      • 5.4.3.7 Stage
      • 5.4.3.8 Services
      • 5.4.3.9 Deployment
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Device
      • 5.4.4.7 Stage
      • 5.4.4.8 Services
      • 5.4.4.9 Deployment
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Device
      • 5.4.5.7 Stage
      • 5.4.5.8 Services
      • 5.4.5.9 Deployment
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Device
      • 5.4.6.7 Stage
      • 5.4.6.8 Services
      • 5.4.6.9 Deployment
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Device
      • 5.4.7.7 Stage
      • 5.4.7.8 Services
      • 5.4.7.9 Deployment
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Device
      • 5.5.1.7 Stage
      • 5.5.1.8 Services
      • 5.5.1.9 Deployment
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Device
      • 5.5.2.7 Stage
      • 5.5.2.8 Services
      • 5.5.2.9 Deployment
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Device
      • 5.5.3.7 Stage
      • 5.5.3.8 Services
      • 5.5.3.9 Deployment
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Device
      • 5.5.4.7 Stage
      • 5.5.4.8 Services
      • 5.5.4.9 Deployment
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Device
      • 5.5.5.7 Stage
      • 5.5.5.8 Services
      • 5.5.5.9 Deployment
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Device
      • 5.5.6.7 Stage
      • 5.5.6.8 Services
      • 5.5.6.9 Deployment
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Device
      • 5.6.1.7 Stage
      • 5.6.1.8 Services
      • 5.6.1.9 Deployment
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Device
      • 5.6.2.7 Stage
      • 5.6.2.8 Services
      • 5.6.2.9 Deployment
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Device
      • 5.6.3.7 Stage
      • 5.6.3.8 Services
      • 5.6.3.9 Deployment
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Device
      • 5.6.4.7 Stage
      • 5.6.4.8 Services
      • 5.6.4.9 Deployment
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Device
      • 5.6.5.7 Stage
      • 5.6.5.8 Services
      • 5.6.5.9 Deployment
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Kazia Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Northwest Biotherapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Del Mar Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cortexyme
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Vascular Biogenics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Agenus
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Merrimack Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Diffusion Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Ziopharm Oncology
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Oncoceutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 DNAtrix
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Immunomic Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Kintara Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Medicenna Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Candel Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Immuno Cellular Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Plus Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Tocagen
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Orbus Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bexion Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us